Company intelligence / Profile preview

Alfresa Pharma

Osaka, Japan

Ownership: Public · 2784
Development stage: Other

Overview

Alfresa Pharma manufactures and develops pharmaceuticals, including branded and generic drugs, active pharmaceutical ingredients (APIs), and contract development and manufacturing services. It also handles medical devices and diagnostics, maintaining ISO13485:2003 certification for several sites. In 2023, it merged with Sannova, expanding its production and R&D capabilities[1]. Clinical results are primarily within established commercialized products.

Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Alfresa Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alfresa Pharma.

Explore the full profile